To include your compound in the COVID-19 Resource Center, submit it here.

Intra-Cellular resolves toxicity concerns over lumateperone

Intra-Cellular Therapies Inc. (NASDAQ:ITCI) said FDA agreed that the company provided adequate data indicating that a toxicity signal seen in animal

Read the full 217 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE